192 related articles for article (PubMed ID: 26523632)
21. Disulfide-bridged cleavable PEGylation in polymeric nanomedicine for controlled therapeutic delivery.
Dong H; Tang M; Li Y; Li Y; Qian D; Shi D
Nanomedicine (Lond); 2015 Jul; 10(12):1941-58. PubMed ID: 26139127
[TBL] [Abstract][Full Text] [Related]
22. Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin.
Mueller C; Capelle MA; Arvinte T; Seyrek E; Borchard G
J Pharm Sci; 2011 May; 100(5):1648-62. PubMed ID: 21374604
[TBL] [Abstract][Full Text] [Related]
23. Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods.
Mero A; Clementi C; Veronese FM; Pasut G
Methods Mol Biol; 2011; 751():95-129. PubMed ID: 21674328
[TBL] [Abstract][Full Text] [Related]
24. Protein PEGylation attenuates adsorption and aggregation on a negatively charged and moderately hydrophobic polymer surface.
Pai SS; Przybycien TM; Tilton RD
Langmuir; 2010 Dec; 26(23):18231-8. PubMed ID: 21067142
[TBL] [Abstract][Full Text] [Related]
25. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
Turecek PL; Bossard MJ; Schoetens F; Ivens IA
J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
[TBL] [Abstract][Full Text] [Related]
26. PEGylation and Cell-Penetrating Peptides: Glimpse into the Past and Prospects in the Future.
Kumar S; Singh D; Kumari P; Malik RS; Poonam ; Parang K; Tiwari RK
Curr Top Med Chem; 2020; 20(5):337-348. PubMed ID: 31994461
[TBL] [Abstract][Full Text] [Related]
27. Preparation and characterization of PEGyated Concanavalin A for affinity chromatography with improved stability.
Wen Z; Niemeyer B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(20):1732-40. PubMed ID: 21571597
[TBL] [Abstract][Full Text] [Related]
28. In vitro refolding of PEGylated lipase.
Kim MY; Kwon JS; Kim HJ; Lee EK
J Biotechnol; 2007 Aug; 131(2):177-9. PubMed ID: 17683821
[TBL] [Abstract][Full Text] [Related]
29. Conformational stability of lyophilized PEGylated proteins in a phase-separating system.
Heller MC; Carpenter JF; Randolph TW
J Pharm Sci; 1999 Jan; 88(1):58-64. PubMed ID: 9874703
[TBL] [Abstract][Full Text] [Related]
30. Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG.
Mero A; Spolaore B; Veronese FM; Fontana A
Bioconjug Chem; 2009 Feb; 20(2):384-9. PubMed ID: 19186937
[TBL] [Abstract][Full Text] [Related]
31. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
Wu L; Ho SV; Wang W; Gao J; Zhang G; Su Z; Hu T
Int J Pharm; 2013 Sep; 453(2):533-40. PubMed ID: 23796830
[TBL] [Abstract][Full Text] [Related]
32. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
[TBL] [Abstract][Full Text] [Related]
33. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
[TBL] [Abstract][Full Text] [Related]
34. Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation.
Mu Q; Hu T; Yu J
PLoS One; 2013; 8(7):e68559. PubMed ID: 23874671
[TBL] [Abstract][Full Text] [Related]
35. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.
Fahrländer E; Schelhaas S; Jacobs AH; Langer K
Nanotechnology; 2015 Apr; 26(14):145103. PubMed ID: 25789544
[TBL] [Abstract][Full Text] [Related]
36. Protein PEGylation decreases observed target association rates via a dual blocking mechanism.
Kubetzko S; Sarkar CA; Plückthun A
Mol Pharmacol; 2005 Nov; 68(5):1439-54. PubMed ID: 16099846
[TBL] [Abstract][Full Text] [Related]
37. Interaction mechanism of mono-PEGylated proteins in electrostatic interaction chromatography.
Abe M; Akbarzaderaleh P; Hamachi M; Yoshimoto N; Yamamoto S
Biotechnol J; 2010 May; 5(5):477-83. PubMed ID: 20440716
[TBL] [Abstract][Full Text] [Related]
38. Self-Assembly PEGylation Retaining Activity (SPRA) Technology via a Host-Guest Interaction Surpassing Conventional PEGylation Methods of Proteins.
Hirotsu T; Higashi T; Abu Hashim II; Misumi S; Wada K; Motoyama K; Arima H
Mol Pharm; 2017 Feb; 14(2):368-376. PubMed ID: 28032772
[TBL] [Abstract][Full Text] [Related]
39. PEGYLATION: an important approach for novel drug delivery system.
Yadav D; Dewangan HK
J Biomater Sci Polym Ed; 2021 Feb; 32(2):266-280. PubMed ID: 32942961
[TBL] [Abstract][Full Text] [Related]
40. PEGylation of therapeutic proteins.
Jevsevar S; Kunstelj M; Porekar VG
Biotechnol J; 2010 Jan; 5(1):113-28. PubMed ID: 20069580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
